TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7849366

Group type: EXPERIMENTAL
Intervention: Anterior circulation (internal carotid arteries)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Posterior circulation (vertebral arteries)
Number of subjects: 21
Study: 1495785

Group type: EXPERIMENTAL
Intervention: Oral acyclovir (800 mg 5 times daily) for 7 days
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Oral acyclovir (800 mg 5 times daily) for 14 days
Number of subjects: 86

Group type: COMPARATOR
Intervention: Untreated patients (as a reference)
Number of subjects: 86
Study: 6496206

Group type: EXPERIMENTAL
Intervention: Reactive condition (telephone contact by an assistant in the original smoking cessation treatment program)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-reactive condition (telephone contact by an employee of a market research firm)
Number of subjects: 0
Study: 30320665

Group type: EXPERIMENTAL
Intervention: Donkey milk-derived fortifier (DF)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Bovine milk-derived fortifier (BF)
Number of subjects: 156
Study: 30571192

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I (hs-cTnI) measurement
Number of subjects: 1767

Group type: EXPERIMENTAL
Intervention: Highest quartile of hs-cTnI
Number of subjects: 1767

Group type: COMPARATOR
Intervention: Spironolactone treatment
Number of subjects: 1767
Study: 27084538

Group type: EXPERIMENTAL
Intervention: Oral elemental diet (ED) - 300 kcal of ED plus regular diet for 6-8 weeks after surgery
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control diet - regular diet alone
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Oral elemental diet (ED) - in total gastrectomy patients
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control diet - in total gastrectomy patients
Number of subjects: 112
Study: 28381222

Group type: EXPERIMENTAL
Intervention: Zarit Burden Interview (ZBI)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Involvement Evaluation Questionnaire (IEQ)
Number of subjects: 223

Group type: COMPARATOR
Intervention: ZBI and IEQ
Number of subjects: 223
Study: 23710734

Group type: EXPERIMENTAL
Intervention: Boceprevir plus peginterferon alfa-2b/ribavirin (triple therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Boceprevir (t.d.s. dosing interval 7-9 h)
Number of subjects: 0
Study: 21777259

Group type: EXPERIMENTAL
Intervention: Brief motivational intervention (BMI)
Number of subjects: 572

Group type: COMPARATOR
Intervention: Control group (waiting list for BMI)
Number of subjects: 572
Study: 19911678

Group type: EXPERIMENTAL
Intervention: C/BPO HE
Number of subjects: 382

Group type: COMPARATOR
Intervention: A/BPO
Number of subjects: 382
Study: 17151593

Group type: EXPERIMENTAL
Intervention: Oat products with increasing beta-glucan content
Number of subjects: 10

Group type: COMPARATOR
Intervention: Reference glucose load
Number of subjects: 10
Study: 15540913

Group type: EXPERIMENTAL
Intervention: Continuous-flow (CF) shunt
Number of subjects: 103

Group type: COMPARATOR
Intervention: Conventional shunt (control group)
Number of subjects: 103
Study: 11176087

Group type: EXPERIMENTAL
Intervention: 0.5% chlorhexidine
Number of subjects: 100
Study: 9573502

Group type: EXPERIMENTAL
Intervention: hBNP 0.025 or 0.05 microgram/kg/min
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 7796899

Group type: EXPERIMENTAL
Intervention: Consistent condom use
Number of subjects: 4023

Group type: EXPERIMENTAL
Intervention: Diaphragm use
Number of subjects: 4023

Group type: EXPERIMENTAL
Intervention: The pill
Number of subjects: 4023

Group type: EXPERIMENTAL
Intervention: IUD
Number of subjects: 4023

Group type: EXPERIMENTAL
Intervention: Vasectomy
Number of subjects: 4023

Group type: EXPERIMENTAL
Intervention: Female sterilization
Number of subjects: 4023
Study: 2084879

Group type: EXPERIMENTAL
Intervention: Nicardipine (40 or 60 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 or 30 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nicardipine
Number of subjects: 12
Study: 395626

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 30660018

Group type: EXPERIMENTAL
Intervention: Indomethacin (1 drop, 4 times a day for 3 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Diclofenac (1 drop, 4 times a day for 3 days)
Number of subjects: 20
Study: 28323237

Group type: EXPERIMENTAL
Intervention: Direct Macintosh laryngoscopy (DL)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: McGrath® MAC video laryngoscope (MM)
Number of subjects: 132
Study: 25361222

Group type: EXPERIMENTAL
Intervention: Ghrelin (0.5 μg/kg/h) for 5 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (pure saline for 5 days)
Number of subjects: 40
Study: 23306726

Group type: EXPERIMENTAL
Intervention: Mitomycin-C augmented trabeculectomy
Number of subjects: 165
Study: 21161666

Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte solution (CHOc)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte solution (CHO)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (PLAc)
Number of subjects: 12
Study: 19241334

Group type: EXPERIMENTAL
Intervention: Rowatinex, 100 mg, 3 times per day
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 17560414

Group type: EXPERIMENTAL
Intervention: Nonsurgical and minimal access strategies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 0
Study: 15291124

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg tid for 4 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 11304896

Group type: EXPERIMENTAL
Intervention: 1 mg dose of atrasentan
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 10 mg dose of atrasentan
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 23.25 mg dose of atrasentan
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 139.5 mg dose of atrasentan
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: All doses of atrasentan
Number of subjects: 24
Study: 9385283

Group type: EXPERIMENTAL
Intervention: Nasal salmon calcitonin (200 IU daily for 28 days)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 100
Study: 9113120

Group type: EXPERIMENTAL
Intervention: Tropisetron (Navoban) monotherapy
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Tropisetron plus dexamethasone
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Tropisetron plus metoclopramide
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Tropisetron and tropisetron plus metoclopramide
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: All antiemetic treatments
Number of subjects: 87
Study: 2140659

Group type: EXPERIMENTAL
Intervention: Tacrine (THA) with succinylcholine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Alcuronium
Number of subjects: 20
Study: 347574

Group type: EXPERIMENTAL
Intervention: Apomorphine (subcutaneous doses)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 31918760

Group type: COMPARATOR
Intervention: Transdiagnostic treatment protocol using an adapted version of the Problem Management Plus (PM+) protocol, consisting of six 90-min sessions.
Number of subjects: 120
Study: 30753642

Group type: EXPERIMENTAL
Intervention: Vaginal tenofovir (TFV) 1% gel
Number of subjects: 566

Group type: COMPARATOR
Intervention: No TFV detected in plasma
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: TFV detection in plasma
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: TFV detection in plasma (adjusted)
Number of subjects: 566
Study: 28271493

Group type: EXPERIMENTAL
Intervention: Orbis' microsphere prednisone formulation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control formulation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference formulation (Roxanne Laboratories)
Number of subjects: 24
Study: 26095784

Group type: EXPERIMENTAL
Intervention: Ramucirumab (8 mg/kg) every 2 weeks
Number of subjects: 565

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: Ramucirumab
Number of subjects: 565
Study: 24169342

Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation (two nursing counselling sessions and two instructive sessions with a physical therapist)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation
Number of subjects: 161

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 161
Study: 21975231

Group type: EXPERIMENTAL
Intervention: Intracoronary autologous transplant of bone marrow-derived stem cells
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (no stem cell treatment)
Number of subjects: 8
Study: 19187518

Group type: EXPERIMENTAL
Intervention: Artesunate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 0
Study: 16899031

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg) or Placebo
Number of subjects: 93
Study: 15205853

Group type: EXPERIMENTAL
Intervention: 7.2 mM sodium nitroprusside (SNP) solution (2.16 mg/ml)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 31
Study: 11348560

Group type: EXPERIMENTAL
Intervention: High-antioxidant diet (5-7 servings of fruit and vegetables per day) for 2 weeks
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Spray-dried antioxidant supplement (30 g) for 2 weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (2-week depletion period with low-antioxidant diet)
Number of subjects: 25
Study: 9421873

Group type: EXPERIMENTAL
Intervention: Bayesian solution using BUGS implementation of Gibbs sampling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naive analyses using observed risk of events in control groups
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naive analyses using average risk in control and treatment groups
Number of subjects: 0
Study: 7956627

Group type: EXPERIMENTAL
Intervention: Liquid-crystal contact thermography (LCT) assessing mean plantar foot temperature (MFT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (patients with PVD)
Number of subjects: 50
Study: 3540836

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (25 IU of dl‐alpha‐tocopherol)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Control group (similar volume of drug vehicle)
Number of subjects: 178
Study: 29019274

Group type: EXPERIMENTAL
Intervention: Strength and balance program combined with whole-body vibration
Number of subjects: 73

Group type: COMPARATOR
Intervention: Strength and balance program without whole-body vibration
Number of subjects: 73
Study: 27523436

Group type: EXPERIMENTAL
Intervention: 500 mg of resveratrol/day for 4 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 20
Study: 24231167

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 206
Study: 23446067

Group type: EXPERIMENTAL
Intervention: Mild lumbar decompression
Number of subjects: 45
Study: 20562078

Group type: EXPERIMENTAL
Intervention: PercuSurge GuardWire system (protection group)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 118
Study: 19472804

Group type: EXPERIMENTAL
Intervention: Paracetamol 1000 mg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg
Number of subjects: 75

Group type: COMPARATOR
Intervention: No preoperative analgesia (Control)
Number of subjects: 75
Study: 15899689

Group type: EXPERIMENTAL
Intervention: Norms about safe work practices
Number of subjects: 2541

Group type: EXPERIMENTAL
Intervention: Norms about smoking
Number of subjects: 2541

Group type: EXPERIMENTAL
Intervention: Norms about healthy eating
Number of subjects: 2541
Study: 12840088

Group type: COMPARATOR
Intervention: CAF (cyclophosphamide, doxorubicin, and fluorouracil)
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: CAF plus high-dose chemotherapy with cyclophosphamide and thiotepa and autologous hematopoietic stem-cell transplantation
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: CAF plus high-dose chemotherapy and stem-cell transplantation
Number of subjects: 540
Study: 10821295

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 8 mg
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 12 mg
Number of subjects: 369

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 369
Study: 8690280

Group type: EXPERIMENTAL
Intervention: Percutaneous endoscopic gastrostomy (PEG)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Octreotide (0.6 mg/24 hr)
Number of subjects: 34
Study: 2002136

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 6407042

Group type: EXPERIMENTAL
Intervention: 3-cyano-imipramine
Number of subjects: 0
Study: 31230825

Group type: EXPERIMENTAL
Intervention: Spironolactone 100 mg daily
Number of subjects: 360

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 360
Study: 30418492

Group type: EXPERIMENTAL
Intervention: Evidence-based practices for improving social communication impairment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modular and targeted interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adaptive treatment designs and Sequential Multiple Assignment Randomized Trial
Number of subjects: 0
Study: 27054823

Group type: EXPERIMENTAL
Intervention: Family Check-up (FCU) intervention
Number of subjects: 998

Group type: EXPERIMENTAL
Intervention: Engagement in FCU services
Number of subjects: 998

Group type: COMPARATOR
Intervention: Nonengagers in FCU services
Number of subjects: 998

Group type: EXPERIMENTAL
Intervention: Engagers in FCU services
Number of subjects: 998
Study: 25174948

Group type: EXPERIMENTAL
Intervention: Chewing gum with CPP‐ACP (GI)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Chewing gum without CPP‐ACP (GII)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group without gum (GIII)
Number of subjects: 72
Study: 22892742

Group type: EXPERIMENTAL
Intervention: Tetraclean
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Largal Ultra
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 17% ethylenediaminetetraacetic acid
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Tubuliclean
Number of subjects: 25
Study: 19237984

Group type: EXPERIMENTAL
Intervention: Remifentanil with Macintosh laryngoscope
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Remifentanil with Glidescope
Number of subjects: 60

Group type: COMPARATOR
Intervention: Total intubation scores
Number of subjects: 60

Group type: COMPARATOR
Intervention: Muscle rigidity
Number of subjects: 60

Group type: COMPARATOR
Intervention: Arterial pressures or heart rate
Number of subjects: 60
Study: 17890465

Group type: EXPERIMENTAL
Intervention: Triangular waveform HFCWO
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sine waveform HFCWO
Number of subjects: 15
Study: 15020170

Group type: EXPERIMENTAL
Intervention: Intervention Group (received reminder-feedback and educational outreach intervention)
Number of subjects: 2992

Group type: COMPARATOR
Intervention: Control Group (received only the screening program)
Number of subjects: 2992
Study: 11817531

Group type: EXPERIMENTAL
Intervention: Vacuum-assisted venous drainage (VAVD)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Gravitational drainage (GD)
Number of subjects: 72
Study: 9524970

Group type: EXPERIMENTAL
Intervention: Single tooth extraction (group II)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Multiple tooth extraction (group III)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Mucoperiosteal flap elevation (group IV)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Baseline (group I)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Broth culture technique
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Paediatric Isolator technique
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Antibiotic susceptibility
Number of subjects: 207
Study: 7640538

Group type: EXPERIMENTAL
Intervention: Chiropractic treatment
Number of subjects: 741

Group type: COMPARATOR
Intervention: Hospital outpatient management
Number of subjects: 741
Study: 2696671

Group type: EXPERIMENTAL
Intervention: Postoperative subconjunctival 5-fluorouracil (5-FU) injections
Number of subjects: 196

Group type: COMPARATOR
Intervention: No postoperative 5-fluorouracil (control group)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Postoperative intraocular pressure (IOP) control
Number of subjects: 196
Study: 21837

Group type: EXPERIMENTAL
Intervention: Ca-containing antacid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ca-free antacid
Number of subjects: 0
Study: 31896620

Group type: EXPERIMENTAL
Intervention: Omaveloxolone 160 mg
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 31623400

Group type: EXPERIMENTAL
Intervention: L-theanine (200 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 28748995

Group type: EXPERIMENTAL
Intervention: Mindfulness intervention (8 weekly 45-minute sessions)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 88
Study: 26010368

Group type: EXPERIMENTAL
Intervention: Informed consent process
Number of subjects: 46
Study: 23758961

Group type: EXPERIMENTAL
Intervention: Trials that received an extension
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Trials with 80% power
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: All trials
Number of subjects: 73
Study: 21830080

Group type: EXPERIMENTAL
Intervention: Pedicle subtraction osteotomy
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control group (asymptomatic patients)
Number of subjects: 154
Study: 19575270

Group type: EXPERIMENTAL
Intervention: Blacks with uncontrolled BP
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Blacks with controlled BP
Number of subjects: 226

Group type: COMPARATOR
Intervention: Whites with uncontrolled BP
Number of subjects: 226

Group type: COMPARATOR
Intervention: Whites with controlled BP
Number of subjects: 226
Study: 17254697

Group type: EXPERIMENTAL
Intervention: TVT-O plus IS
Number of subjects: 96

Group type: COMPARATOR
Intervention: TVT-O alone
Number of subjects: 96
Study: 15126747

Group type: EXPERIMENTAL
Intervention: Tonsillotomy (TT) using radiofrequency (RF) technique
Number of subjects: 150

Group type: COMPARATOR
Intervention: Traditional tonsillectomy (TE)
Number of subjects: 150
Study: 11677476

Group type: EXPERIMENTAL
Intervention: Multibite forceps
Number of subjects: 250

Group type: COMPARATOR
Intervention: Conventional forceps
Number of subjects: 250
Study: 10216644

Group type: EXPERIMENTAL
Intervention: Low dose aspirin
Number of subjects: 50
Study: 8161260

Group type: EXPERIMENTAL
Intervention: Partial shunt (8‐mm diameter portacaval H grafts with collateral ablation, n = 14)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Total shunt (16‐mm diameter grafts, n = 16)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Partial shunt
Number of subjects: 30

Group type: COMPARATOR
Intervention: Total shunt
Number of subjects: 30
Study: 3415549

Group type: EXPERIMENTAL
Intervention: Ground-glass diffusers (46% to 98% scattering)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Ground-glass diffusers (75% contrast target)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Ground-glass diffusers (5% contrast target)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Visual acuity measurements with projected high-contrast targets
Number of subjects: 5
Study: 31000508

Group type: EXPERIMENTAL
Intervention: Subconjunctival injection of 2.5 mg dexamethasone
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no dexamethasone injection)
Number of subjects: 42
Study: 30948284

Group type: EXPERIMENTAL
Intervention: Revealed testing (PlGF measurement revealed to clinicians)
Number of subjects: 1023

Group type: COMPARATOR
Intervention: Concealed testing (PlGF measurement concealed from clinicians)
Number of subjects: 1023

Group type: EXPERIMENTAL
Intervention: Revealed testing
Number of subjects: 1023

Group type: COMPARATOR
Intervention: Concealed testing
Number of subjects: 1023
Study: 26911532

Group type: EXPERIMENTAL
Intervention: Family member-based supervision package
Number of subjects: 554

Group type: COMPARATOR
Intervention: Usual service
Number of subjects: 554
Study: 25590358

Group type: EXPERIMENTAL
Intervention: Griffonia simplicifolia/magnesium complex (50 and 200 mg, respectively), orally administered twice a day for 3 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: No therapy for MS
Number of subjects: 0
Study: 23442276

Group type: EXPERIMENTAL
Intervention: Stabilization training group (TG, n = 16)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (n = 12)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 28
Study: 22029641

Group type: EXPERIMENTAL
Intervention: short‐acting MPH (0.5 mg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 17914251

Group type: EXPERIMENTAL
Intervention: Oral paricalcitol
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 16981274

Group type: EXPERIMENTAL
Intervention: Weiansan (WAS) 5 g, 3 times a day
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Weifuchun (WFC) 4 tablets, 3 times a day
Number of subjects: 76

Group type: COMPARATOR
Intervention: Model group (ranitidine + MNNG)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: High-dose WAS
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Low-dose WAS
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Weifuchun (WFC)
Number of subjects: 76
Study: 12604410

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study: 11083243

Group type: EXPERIMENTAL
Intervention: CARTO-guided radiofrequency catheter ablation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional radiofrequency catheter ablation
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both CARTO-guided and conventional approaches
Number of subjects: 80